T Ushiroyama1, A Ikeda, M Ueki. 1. Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki 569-8686, Osaka, Japan. gyn003@poh.osaka-med.ac.jp
Abstract
OBJECTIVES: The aims of the present study are to assess the 5 year effects of pravastatin on serum lipids and lipoproteins in women around the menopause and to assess the effects of pravastatin on serum gonadotropins and sex steroid levels over a long-term period. METHODS: We evaluated the long-term efficacy of pravastatin on serum lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride) in 121 patients (47 premenopausal and 74 postmenopausal women) suffering from primary hypercholesterolemia. The effects of this lipid-lowering drug on serum gonadotropins and sex steroids (estradiol, estrone, and testosterone) are also reported. RESULTS: Pravastatin produced a remarkable reduction in the serum total cholesterol level of 19.2+/-9.3% (P<0.0001) and 18.9+/-11.8% (P<0.0001), and in LDLl-cholesterol of 25.1+/-18.7% (P<0.0001) and 24+/-18.0% (P<0.0001) after 24 and 60 months' treatment, respectively. In hypertriglyceridemia, pravastatin also produced a remarkable reduction in triglyceride of 29.3+/-27.3% (P<0.0001) and 39.9+/-20.4% (P<0.0001) after 24 and 60 months of treatment, respectively. We found that serum gonadotropins and sex steroid levels changed naturally as a function of age from pre-therapy levels in the premenopausal patients after 60 months of treatment. CONCLUSIONS: Pravastatin was well tolerated over 5 years and was a very effective lipid-lowering agent for both hypercholesterolemia and hypertriglyceridemia with no effect on the biosynthesis of sex steroids. These findings suggest that pravastatin can be used in the treatment of hypercholesterolemia with/without high triglyceride levels in women around the menopause.
OBJECTIVES: The aims of the present study are to assess the 5 year effects of pravastatin on serum lipids and lipoproteins in women around the menopause and to assess the effects of pravastatin on serum gonadotropins and sex steroid levels over a long-term period. METHODS: We evaluated the long-term efficacy of pravastatin on serum lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride) in 121 patients (47 premenopausal and 74 postmenopausal women) suffering from primary hypercholesterolemia. The effects of this lipid-lowering drug on serum gonadotropins and sex steroids (estradiol, estrone, and testosterone) are also reported. RESULTS:Pravastatin produced a remarkable reduction in the serum total cholesterol level of 19.2+/-9.3% (P<0.0001) and 18.9+/-11.8% (P<0.0001), and in LDLl-cholesterol of 25.1+/-18.7% (P<0.0001) and 24+/-18.0% (P<0.0001) after 24 and 60 months' treatment, respectively. In hypertriglyceridemia, pravastatin also produced a remarkable reduction in triglyceride of 29.3+/-27.3% (P<0.0001) and 39.9+/-20.4% (P<0.0001) after 24 and 60 months of treatment, respectively. We found that serum gonadotropins and sex steroid levels changed naturally as a function of age from pre-therapy levels in the premenopausal patients after 60 months of treatment. CONCLUSIONS:Pravastatin was well tolerated over 5 years and was a very effective lipid-lowering agent for both hypercholesterolemia and hypertriglyceridemia with no effect on the biosynthesis of sex steroids. These findings suggest that pravastatin can be used in the treatment of hypercholesterolemia with/without high triglyceride levels in women around the menopause.
Authors: Oludamilola W Oluleye; Richard A Kronmal; Aaron R Folsom; Dhananjay M Vaidya; Pamela Ouyang; Daniel A Duprez; Adrian S Dobs; Hirad Yarmohammadi; Suma H Konety Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958